Figure 4.

The BiSS antibody inhibits cancer growth in vivo. NOD/SCID mice (n = 5/group) were engrafted subcutaneously with LS174T cells with or without human PBMCs as described in the Methods and Materials. Three groups of mice were then treated. Two control groups, mice transplanted with LS174T only, no PBMC (solid square), or mice transplanted with both LS174T and PBMC (open triangle) were treated with PBS only. One group of mice transplanted with both LS174T and PBMC were treated with BiSS (20 μg per mouse daily) (solid diamond). The data represent the average cancer volume of 5 mice with the error bars representing the standard deviation (*P < 0.01, t test, BiSS vs the other 2 groups).